{"transactions":[{"id":692143,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-10T13:00:42.000Z","date":"2026-08-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":1467,"price":13.34,"value":19569.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022."}],"balance_after":23787,"source":{"system":"sec-edgar","filing":"0002064832-26-000266","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000266/form4.xml","form_type":"4"}},{"id":844343,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61042,"kind":"person","name":"Vance Terry","position":1,"cik":"0001572282","reported_name":"Vance Terry","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-13T20:20:56.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":14.17,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002064832-26-000143","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000143/form4.xml","form_type":"4"}},{"id":844342,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61041,"kind":"person","name":"Russell Lesley","position":1,"cik":"0001374636","reported_name":"Russell Lesley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-13T20:19:48.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":14.17,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002064832-26-000142","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000142/form4.xml","form_type":"4"}},{"id":844341,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":36325,"kind":"person","name":"Peterson Kristine","position":1,"cik":"0001508596","reported_name":"Peterson Kristine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-13T20:18:09.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":14.17,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002064832-26-000141","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000141/form4.xml","form_type":"4"}},{"id":844340,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61040,"kind":"person","name":"Hata Yujiro S","position":1,"cik":"0001649119","reported_name":"Hata Yujiro S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-13T20:17:04.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":14.17,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002064832-26-000140","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000140/form4.xml","form_type":"4"}},{"id":844339,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":26831,"kind":"person","name":"FOLETTA MARK G","position":1,"cik":"0001236389","reported_name":"FOLETTA MARK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-13T20:15:36.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":14.17,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002064832-26-000139","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000139/form4.xml","form_type":"4"}},{"id":844338,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61039,"kind":"person","name":"CARTER BRUCE L A","position":1,"cik":"0001225503","reported_name":"CARTER BRUCE L A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-13T20:14:14.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":14.17,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002064832-26-000138","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000138/form4.xml","form_type":"4"}},{"id":905488,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:33:34.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":1902,"price":14.25,"value":27103.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":3591,"source":{"system":"sec-edgar","filing":"0002064832-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/form4.xml","form_type":"4"}},{"id":905487,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:33:34.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":5493,"source":{"system":"sec-edgar","filing":"0002064832-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/form4.xml","form_type":"4"}},{"id":905486,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:33:34.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":1318,"source":{"system":"sec-edgar","filing":"0002064832-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/form4.xml","form_type":"4"}},{"id":905491,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:31:44.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3257,"price":14.25,"value":46412.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":41634,"source":{"system":"sec-edgar","filing":"0002064832-26-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000014/form4.xml","form_type":"4"}},{"id":905490,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:31:44.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":44891,"source":{"system":"sec-edgar","filing":"0002064832-26-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000014/form4.xml","form_type":"4"}},{"id":905489,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:31:44.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":39904,"source":{"system":"sec-edgar","filing":"0002064832-26-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000014/form4.xml","form_type":"4"}},{"id":905485,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:29:51.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3257,"price":14.25,"value":46412.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":33925,"source":{"system":"sec-edgar","filing":"0002064832-26-000012","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000012/form4.xml","form_type":"4"}},{"id":905484,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:29:51.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":37182,"source":{"system":"sec-edgar","filing":"0002064832-26-000012","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000012/form4.xml","form_type":"4"}},{"id":905483,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:29:51.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":32195,"source":{"system":"sec-edgar","filing":"0002064832-26-000012","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000012/form4.xml","form_type":"4"}},{"id":905482,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:28:45.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3413,"price":14.25,"value":48635.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":25254,"source":{"system":"sec-edgar","filing":"0002064832-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000010/form4.xml","form_type":"4"}},{"id":905481,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:28:45.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":5225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":28667,"source":{"system":"sec-edgar","filing":"0002064832-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000010/form4.xml","form_type":"4"}},{"id":905480,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:28:45.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":23442,"source":{"system":"sec-edgar","filing":"0002064832-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000010/form4.xml","form_type":"4"}},{"id":905479,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:27:26.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3413,"price":14.25,"value":48635.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":374854,"source":{"system":"sec-edgar","filing":"0002064832-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000008/form4.xml","form_type":"4"}},{"id":905478,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:27:26.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":5225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":378267,"source":{"system":"sec-edgar","filing":"0002064832-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000008/form4.xml","form_type":"4"}},{"id":905477,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:27:26.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":373042,"source":{"system":"sec-edgar","filing":"0002064832-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000008/form4.xml","form_type":"4"}},{"id":905476,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T21:25:07.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":6155,"price":14.25,"value":87708.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":871871,"source":{"system":"sec-edgar","filing":"0002064832-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/form4.xml","form_type":"4"}},{"id":905475,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T21:25:07.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":878026,"source":{"system":"sec-edgar","filing":"0002064832-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/form4.xml","form_type":"4"}},{"id":905474,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T21:25:07.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":862826,"source":{"system":"sec-edgar","filing":"0002064832-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/form4.xml","form_type":"4"}},{"id":979323,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72165,"kind":"person","name":"Capps Kathleen S.","position":1,"cik":"0002085127","reported_name":"Capps Kathleen S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-05T23:53:20.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":323,"price":14.23,"value":4596.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":8377,"source":{"system":"sec-edgar","filing":"0002064832-25-000070","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000070/form4.xml","form_type":"4"}},{"id":979322,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72164,"kind":"person","name":"Trout Harry R. III","position":1,"cik":"0002085123","reported_name":"Trout Harry R. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-05T23:47:53.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":542,"price":14.23,"value":7712.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":16348,"source":{"system":"sec-edgar","filing":"0002064832-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000067/form4.xml","form_type":"4"}},{"id":979321,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-05T23:46:32.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":798,"price":14.23,"value":11355.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":21792,"source":{"system":"sec-edgar","filing":"0002064832-25-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000065/form4.xml","form_type":"4"}},{"id":979319,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-12-05T23:45:19.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":1394,"price":14.23,"value":19836.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":38329,"source":{"system":"sec-edgar","filing":"0002064832-25-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000063/form4.xml","form_type":"4"}},{"id":979320,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2025-12-05T23:44:17.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":2106,"price":14.23,"value":29968.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":30620,"source":{"system":"sec-edgar","filing":"0002064832-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000061/form4.xml","form_type":"4"}},{"id":979317,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-05T23:43:01.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":2390,"price":14.23,"value":34009.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":371392,"source":{"system":"sec-edgar","filing":"0002064832-25-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000059/form4.xml","form_type":"4"}},{"id":979318,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-05T23:41:50.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":4743,"price":14.23,"value":67492.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":858026,"source":{"system":"sec-edgar","filing":"0002064832-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000057/form4.xml","form_type":"4"}},{"id":982052,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72165,"kind":"person","name":"Capps Kathleen S.","position":1,"cik":"0002085127","reported_name":"Capps Kathleen S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-03T22:09:07.000Z","date":"2025-12-02","kind":"sale","planned":false,"acquired":false,"shares":207,"price":13.96,"value":2889.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 27, 2024, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."}],"balance_after":8700,"source":{"system":"sec-edgar","filing":"0002064832-25-000053","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000053/form4.xml","form_type":"4"}},{"id":982051,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72165,"kind":"person","name":"Capps Kathleen S.","position":1,"cik":"0002085127","reported_name":"Capps Kathleen S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-03T22:09:07.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":85,"price":14.12,"value":1200.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":8907,"source":{"system":"sec-edgar","filing":"0002064832-25-000053","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000053/form4.xml","form_type":"4"}},{"id":982054,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72164,"kind":"person","name":"Trout Harry R. III","position":1,"cik":"0002085123","reported_name":"Trout Harry R. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-03T22:05:25.000Z","date":"2025-12-02","kind":"sale","planned":false,"acquired":false,"shares":380,"price":13.96,"value":5304.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 27, 2024, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."}],"balance_after":16890,"source":{"system":"sec-edgar","filing":"0002064832-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000050/form4.xml","form_type":"4"}},{"id":982053,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72164,"kind":"person","name":"Trout Harry R. III","position":1,"cik":"0002085123","reported_name":"Trout Harry R. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-03T22:05:25.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":105,"price":14.12,"value":1482.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":17270,"source":{"system":"sec-edgar","filing":"0002064832-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000050/form4.xml","form_type":"4"}},{"id":982050,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-12-03T22:02:10.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":498,"price":14.12,"value":7031.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":39723,"source":{"system":"sec-edgar","filing":"0002064832-25-000048","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000048/form4.xml","form_type":"4"}},{"id":982047,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2025-12-03T21:37:53.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":753,"price":14.12,"value":10632.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":32726,"source":{"system":"sec-edgar","filing":"0002064832-25-000046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000046/form4.xml","form_type":"4"}},{"id":982049,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-03T21:36:07.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":753,"price":14.12,"value":10632.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":373782,"source":{"system":"sec-edgar","filing":"0002064832-25-000044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000044/form4.xml","form_type":"4"}},{"id":982048,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-03T21:34:07.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1885,"price":14.12,"value":26616.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":862769,"source":{"system":"sec-edgar","filing":"0002064832-25-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000042/form4.xml","form_type":"4"}},{"id":987436,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72165,"kind":"person","name":"Capps Kathleen S.","position":1,"cik":"0002085127","reported_name":"Capps Kathleen S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:24:51.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":6325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":6325,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":6325},"source":{"system":"sec-edgar","filing":"0002064832-25-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000038/form4.xml","form_type":"4"}},{"id":987435,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72165,"kind":"person","name":"Capps Kathleen S.","position":1,"cik":"0002085127","reported_name":"Capps Kathleen S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-26T22:24:51.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":3163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter."}],"balance_after":8992,"source":{"system":"sec-edgar","filing":"0002064832-25-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000038/form4.xml","form_type":"4"}},{"id":987434,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72164,"kind":"person","name":"Trout Harry R. III","position":1,"cik":"0002085123","reported_name":"Trout Harry R. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:20:59.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":12925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":12925,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":12925},"source":{"system":"sec-edgar","filing":"0002064832-25-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000036/form4.xml","form_type":"4"}},{"id":987433,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":72164,"kind":"person","name":"Trout Harry R. III","position":1,"cik":"0002085123","reported_name":"Trout Harry R. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-26T22:20:59.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":6463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter."}],"balance_after":17375,"source":{"system":"sec-edgar","filing":"0002064832-25-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000036/form4.xml","form_type":"4"}},{"id":987432,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:14:40.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":90000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0002064832-25-000034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000034/form4.xml","form_type":"4"}},{"id":987430,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:11:05.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":100000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0002064832-25-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000032/form4.xml","form_type":"4"}},{"id":987428,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:08:15.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":90000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0002064832-25-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000030/form4.xml","form_type":"4"}},{"id":987429,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:05:39.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":110000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0002064832-25-000028","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000028/form4.xml","form_type":"4"}},{"id":987427,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:03:25.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":110000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0002064832-25-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000026/form4.xml","form_type":"4"}},{"id":987431,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:01:14.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":310000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0002064832-25-000024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000024/form4.xml","form_type":"4"}},{"id":1071550,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-08T20:35:45.000Z","date":"2025-08-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":2217,"price":6.99,"value":15496.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022."}],"balance_after":22590,"source":{"system":"sec-edgar","filing":"0001062993-25-013981","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325013981/form4.xml","form_type":"4"}},{"id":1206010,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61042,"kind":"person","name":"Vance Terry","position":1,"cik":"0001572282","reported_name":"Vance Terry","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T21:44:01.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":6.83,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-25-005507","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325005507/form4.xml","form_type":"4"}},{"id":1206009,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61041,"kind":"person","name":"Russell Lesley","position":1,"cik":"0001374636","reported_name":"Russell Lesley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T21:43:30.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":6.83,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-25-005506","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325005506/form4.xml","form_type":"4"}},{"id":1206008,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":36325,"kind":"person","name":"Peterson Kristine","position":1,"cik":"0001508596","reported_name":"Peterson Kristine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T21:43:00.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":6.83,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-25-005505","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325005505/form4.xml","form_type":"4"}},{"id":1206006,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61040,"kind":"person","name":"Hata Yujiro S","position":1,"cik":"0001649119","reported_name":"Hata Yujiro S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T21:35:47.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":6.83,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-25-005504","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325005504/form4.xml","form_type":"4"}},{"id":1206007,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":26831,"kind":"person","name":"FOLETTA MARK G","position":1,"cik":"0001236389","reported_name":"FOLETTA MARK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T21:34:30.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":6.83,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-25-005503","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325005503/form4.xml","form_type":"4"}},{"id":1206003,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61039,"kind":"person","name":"CARTER BRUCE L A","position":1,"cik":"0001225503","reported_name":"CARTER BRUCE L A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T21:33:12.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":6.83,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-25-005502","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325005502/form4.xml","form_type":"4"}},{"id":1267834,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:46:35.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3326,"price":5.59,"value":18592.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":40221,"source":{"system":"sec-edgar","filing":"0001062993-25-002568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002568/form4.xml","form_type":"4"}},{"id":1267833,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:46:35.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":43547,"source":{"system":"sec-edgar","filing":"0001062993-25-002568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002568/form4.xml","form_type":"4"}},{"id":1267831,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:44:16.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3326,"price":5.59,"value":18592.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":33479,"source":{"system":"sec-edgar","filing":"0001062993-25-002563","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002563/form4.xml","form_type":"4"}},{"id":1267830,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:44:16.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":36805,"source":{"system":"sec-edgar","filing":"0001062993-25-002563","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002563/form4.xml","form_type":"4"}},{"id":1267827,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:42:37.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":2861,"price":5.59,"value":15992.99,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":24807,"source":{"system":"sec-edgar","filing":"0001062993-25-002561","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002561/form4.xml","form_type":"4"}},{"id":1267826,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:42:37.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":27668,"source":{"system":"sec-edgar","filing":"0001062993-25-002561","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002561/form4.xml","form_type":"4"}},{"id":1267829,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:40:00.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":4324,"price":5.59,"value":24171.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":374535,"source":{"system":"sec-edgar","filing":"0001062993-25-002558","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002558/form4.xml","form_type":"4"}},{"id":1267828,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:40:00.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":378859,"source":{"system":"sec-edgar","filing":"0001062993-25-002558","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002558/form4.xml","form_type":"4"}},{"id":1267825,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":83218,"kind":"person","name":"MELLETT PAUL J","position":1,"cik":"0001185034","reported_name":"MELLETT PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Admin Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:37:57.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":3326,"price":5.59,"value":18592.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":95884,"source":{"system":"sec-edgar","filing":"0001062993-25-002553","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002553/form4.xml","form_type":"4"}},{"id":1267824,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":83218,"kind":"person","name":"MELLETT PAUL J","position":1,"cik":"0001185034","reported_name":"MELLETT PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Admin Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:37:57.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":99210,"source":{"system":"sec-edgar","filing":"0001062993-25-002553","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002553/form4.xml","form_type":"4"}},{"id":1267823,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T21:35:58.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":7484,"price":5.59,"value":41835.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":864654,"source":{"system":"sec-edgar","filing":"0001062993-25-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002549/form4.xml","form_type":"4"}},{"id":1267822,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T21:35:58.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":25500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":872138,"source":{"system":"sec-edgar","filing":"0001062993-25-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002549/form4.xml","form_type":"4"}},{"id":1272051,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-13T01:09:35.000Z","date":"2025-02-12","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":5.69,"value":256050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 5,142 shares, all of which related to a \"sell to cover\" transaction required to satisfy tax withholding obligations due as a result of settlement of a portion of a restricted stock unit award granted on November 23, 2022. The reporting person has paid to Enanta $13,861.92, representing the full amount of the profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.86, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":846638,"source":{"system":"sec-edgar","filing":"0001062993-25-002225","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002225/form4.xml","form_type":"4"}},{"id":1337528,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2024-12-10T22:12:17.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":2283,"price":8.06,"value":18400.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":29305,"source":{"system":"sec-edgar","filing":"0001062993-24-020386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020386/form4.xml","form_type":"4"}},{"id":1337527,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-10T22:08:43.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":2283,"price":8.06,"value":18400.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":36047,"source":{"system":"sec-edgar","filing":"0001062993-24-020384","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020384/form4.xml","form_type":"4"}},{"id":1337526,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-10T22:03:53.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":866,"price":8.06,"value":6979.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":17918,"source":{"system":"sec-edgar","filing":"0001062993-24-020382","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020382/form4.xml","form_type":"4"}},{"id":1337525,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-10T22:00:38.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":2591,"price":8.06,"value":20883.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":369109,"source":{"system":"sec-edgar","filing":"0001062993-24-020380","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020380/form4.xml","form_type":"4"}},{"id":1337524,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":83218,"kind":"person","name":"MELLETT PAUL J","position":1,"cik":"0001185034","reported_name":"MELLETT PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Admin Officer"}}],"security":"Common Stock","published_at":"2024-12-10T21:58:02.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":2591,"price":8.06,"value":20883.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":91710,"source":{"system":"sec-edgar","filing":"0001062993-24-020378","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020378/form4.xml","form_type":"4"}},{"id":1337523,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-10T21:55:03.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":5142,"price":8.06,"value":41444.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":801638,"source":{"system":"sec-edgar","filing":"0001062993-24-020375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020375/form4.xml","form_type":"4"}},{"id":1345553,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-03T23:41:13.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":753,"price":8.6,"value":6475.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":38330,"source":{"system":"sec-edgar","filing":"0001062993-24-019990","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019990/form4.xml","form_type":"4"}},{"id":1345552,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2024-12-03T23:37:58.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":753,"price":8.6,"value":6475.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":31588,"source":{"system":"sec-edgar","filing":"0001062993-24-019987","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019987/form4.xml","form_type":"4"}},{"id":1345551,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-03T23:35:08.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1595,"price":8.6,"value":13717.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021."}],"balance_after":371700,"source":{"system":"sec-edgar","filing":"0001062993-24-019982","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019982/form4.xml","form_type":"4"}},{"id":1345550,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":83218,"kind":"person","name":"MELLETT PAUL J","position":1,"cik":"0001185034","reported_name":"MELLETT PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Admin Officer"}}],"security":"Common Stock","published_at":"2024-12-03T23:32:11.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1595,"price":8.6,"value":13717.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021."}],"balance_after":94301,"source":{"system":"sec-edgar","filing":"0001062993-24-019980","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019980/form4.xml","form_type":"4"}},{"id":1345549,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-03T23:28:56.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3829,"price":8.6,"value":32929.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021."}],"balance_after":806780,"source":{"system":"sec-edgar","filing":"0001062993-24-019974","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019974/form4.xml","form_type":"4"}},{"id":1349795,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:10:18.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":75000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001062993-24-019776","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019776/form4.xml","form_type":"4"}},{"id":1349794,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66537,"kind":"person","name":"Luu Brendan","position":1,"cik":"0001842369","reported_name":"Luu Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:08:40.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":75000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001062993-24-019774","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019774/form4.xml","form_type":"4"}},{"id":1349793,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:06:52.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":81000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001062993-24-019772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019772/form4.xml","form_type":"4"}},{"id":1349792,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:04:52.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":87000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001062993-24-019770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019770/form4.xml","form_type":"4"}},{"id":1349791,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66534,"kind":"person","name":"Or Yat Sun","position":1,"cik":"0001571212","reported_name":"Or Yat Sun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:03:20.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":87000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001062993-24-019768","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019768/form4.xml","form_type":"4"}},{"id":1349790,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":83218,"kind":"person","name":"MELLETT PAUL J","position":1,"cik":"0001185034","reported_name":"MELLETT PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. & Admin Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:01:49.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":81000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001062993-24-019766","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019766/form4.xml","form_type":"4"}},{"id":1349789,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T21:59:10.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":250000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001062993-24-019764","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019764/form4.xml","form_type":"4"}},{"id":1437087,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-09T21:24:47.000Z","date":"2024-08-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":1466,"price":12.73,"value":18662.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022."}],"balance_after":18784,"source":{"system":"sec-edgar","filing":"0001062993-24-014792","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324014792/form4.xml","form_type":"4"}},{"id":1437086,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-09T21:24:47.000Z","date":"2023-08-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":1467,"price":17.23,"value":25276.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Such amount excludes securities acquired or disposed of subsequent to August 8, 2023."}],"balance_after":25533,"source":{"system":"sec-edgar","filing":"0001062993-24-014792","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324014792/form4.xml","form_type":"4"}},{"id":1454753,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-15T21:29:25.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":false,"shares":5375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023)."}],"balance_after":80625,"derivative":{"exercise_price":8.99,"expiration_date":"2033-11-22","underlying":"Common Stock","underlying_shares":5375},"source":{"system":"sec-edgar","filing":"0001062993-24-013820","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324013820/form4.xml","form_type":"4"}},{"id":1454752,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-15T21:29:25.000Z","date":"2024-07-15","kind":"sale","planned":true,"acquired":false,"shares":5375,"price":17.08,"value":91805.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive."}],"balance_after":21717,"source":{"system":"sec-edgar","filing":"0001062993-24-013820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324013820/form4.xml","form_type":"4"}},{"id":1454751,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-15T21:29:25.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":true,"shares":5375,"price":8.99,"value":48321.25,"ownership":{"direct":true},"balance_after":27092,"source":{"system":"sec-edgar","filing":"0001062993-24-013820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324013820/form4.xml","form_type":"4"}},{"id":1454750,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-15T21:29:25.000Z","date":"2024-07-12","kind":"sale","planned":true,"acquired":false,"shares":2271,"price":15.04,"value":34155.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive."}],"balance_after":21717,"source":{"system":"sec-edgar","filing":"0001062993-24-013820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324013820/form4.xml","form_type":"4"}},{"id":1454749,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":25115,"kind":"person","name":"Rottinghaus Scott T.","position":1,"cik":"0001942407","reported_name":"Rottinghaus Scott T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-15T21:29:25.000Z","date":"2024-07-11","kind":"sale","planned":true,"acquired":false,"shares":4299,"price":15.07,"value":64785.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive."}],"balance_after":23988,"source":{"system":"sec-edgar","filing":"0001062993-24-013820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324013820/form4.xml","form_type":"4"}},{"id":1477578,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66535,"kind":"person","name":"Kieffer Tara Lynn","position":1,"cik":"0001834835","reported_name":"Kieffer Tara Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Product Strategy Officer"}}],"security":"Common Stock","published_at":"2024-06-18T00:38:39.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":7266,"price":12.33,"value":89589.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.54, inclusive."}],"balance_after":32341,"source":{"system":"sec-edgar","filing":"0001062993-24-012734","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324012734/form4.xml","form_type":"4"}},{"id":1532178,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:27:12.000Z","date":"2024-04-29","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of such option will become exercisable on April 29, 2025 (the \"Anniversary Date\"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment)."}],"balance_after":150000,"derivative":{"exercise_price":13.25,"expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001062993-24-009175","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324009175/form4.xml","form_type":"4"}},{"id":1587272,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61042,"kind":"person","name":"Vance Terry","position":1,"cik":"0001572282","reported_name":"Vance Terry","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T22:30:24.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":15.66,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-24-006052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324006052/form4.xml","form_type":"4"}},{"id":1587270,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":61041,"kind":"person","name":"Russell Lesley","position":1,"cik":"0001374636","reported_name":"Russell Lesley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T22:27:40.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":15.66,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-24-006050","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324006050/form4.xml","form_type":"4"}},{"id":1587269,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":36325,"kind":"person","name":"Peterson Kristine","position":1,"cik":"0001508596","reported_name":"Peterson Kristine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T22:23:55.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders."}],"balance_after":15700,"derivative":{"exercise_price":15.66,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001062993-24-006046","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324006046/form4.xml","form_type":"4"}}],"next_cursor":"2024-03-08T22:23:55.000000Z,1587269"}